KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defi

Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studiesCompany expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024SEATTLE--(BUSINESS WIRE)--KayoThera, Inc. (“KayoThera”), an early-stage th...

Related Keywords

Jessica Burback ,Yibin Kang ,Mark Esposito ,Petra Pharma ,Kendall Mohler ,Kayothera Inc ,Us Food Drug Administration ,Proniras Corporation ,Princeton University ,Amgen Inc ,Investigational New Drug ,Drug Administration ,Life Science Partners ,Lodo Therapeutics ,Ginkgo Bioworks ,Rodeo Therapeutics ,